{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:29Z","timestamp":1786998389346,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":76,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ymgme.2013.01.009","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T22:32:13Z","timestamp":1359153133000},"page":"86-92","source":"Crossref","is-referenced-by-count":67,"title":["A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects"],"prefix":"10.1016","volume":"109","author":[{"given":"R.","family":"Giugliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Waldek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Simosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Bragat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.R.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.F.","family":"Boudes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ymgme.2013.01.009_bb0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"10.1016\/j.ymgme.2013.01.009_bb0010","first-page":"1","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2013.01.009_bb0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"4773","key":"10.1016\/j.ymgme.2013.01.009_bb0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/190372a0","article-title":"Gene action in the X-chromosome of the mouse (Mus musculus L.)","volume":"190","author":"Lyon","year":"1961","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ymgme.2013.01.009_bb0095","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0021-9258(19)69965-5","article-title":"Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms","volume":"256","author":"Bishop","year":"1981","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ymgme.2013.01.009_bb0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","article-title":"Screening for pharmacological chaperones in Fabry disease","volume":"359","author":"Shin","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.ymgme.2013.01.009_bb0035","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.ymgme.2013.01.009_bb0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1373\/clinchem.2004.038323","article-title":"Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy","volume":"51","author":"Roddy","year":"2005","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.ymgme.2013.01.009_bb0105","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.ymgme.2013.01.009_bb0050","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.ymgme.2013.01.009_bb0055","doi-asserted-by":"crossref","first-page":"816","DOI":"10.5858\/arpa.2011-0350-OA","article-title":"Novel quantitative quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with Fabry disease","volume":"136","author":"Barisoni","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2013.01.009_bb0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases \u03b1-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2013.01.009_bb0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2013.01.009_bb0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of the pharmacological chaperone migalastat hydrochloride on \u03b1-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2013.01.009_bb0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal a-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2013.01.009_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1172-5-14","article-title":"Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review","volume":"5","author":"Pinto","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2013.01.009_bb0110","series-title":"Presented at the 7th Annual WORLD Symposium. Poster 113","article-title":"Long-term safety, tolerability, and assessments of renal function in adult Fabry patients receiving treatment with AT1001 (migalastat hydrochloride), a pharmacological chaperone","author":"Schiffmann","year":"2011"},{"key":"10.1016\/j.ymgme.2013.01.009_bb0090","unstructured":"F. Johnson, et al., Pharmacokinetics and Safety of Migalastat HCl and Effects on Algasidase activity in Healthy Volunteers, Clin. Pharm. Drug Dev. (in press)."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T15:58:16Z","timestamp":1644163096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719213000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1096719213000310"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2013.01.009","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}